Vyripharm Biopharmaceuticals
Houston-based biotechnology and biopharmaceutical company focusing on integration of agricultural and clinical sciences. Stated activities include development of an integrated data platform linking agricultural and clinical datasets, AI-driven analytics and visualization, laboratory automation, coordination with contract manufacturers for cGMP production, theranostic R&D, early clinical development enablement, and programs for testing, certification and traceability of agribiopharmaceutical products.
Industries
Nr. of Employees
small (1-50)
Vyripharm Biopharmaceuticals
Houston, Texas, United States, North America
Products
Integrated agribiopharmaceutical data platform
Platform design intended to unify data procurement, evaluation and management from agricultural bioproducts through clinical biotechnology to support research, certification and therapeutic development.
BioSync™ Platform
The BioSync™ Platform integrates agribiopharmaceuticals/biotechnology and biopharmaceutical/biotechnology data acquisition and management, combining data procurement, evaluation, and advanced informatics.
VpH Regulatory Testing Platform
A comprehensive framework that provides sophisticated guidance for the industry, ensuring uniformity, differentiation, and standardization in compliance and testing.
Diagnostic & Therapeutic Imaging/Treatment Platform
An integrated theranostic technology platform combining diagnostics and therapeutics for image-guided therapy, advancing drug candidates through Phase Zero.
BI2TM
A blockchain technology and artificial intelligence platform designed to bridge the gap between cultivators, processors, R&D, Global Pharma/biotechnology and the medical community by providing an immutable ledger for supply chain data.
Integrated agribiopharmaceutical data platform
Platform design intended to unify data procurement, evaluation and management from agricultural bioproducts through clinical biotechnology to support research, certification and therapeutic development.
BioSync™ Platform
The BioSync™ Platform integrates agribiopharmaceuticals/biotechnology and biopharmaceutical/biotechnology data acquisition and management, combining data procurement, evaluation, and advanced informatics.
VpH Regulatory Testing Platform
A comprehensive framework that provides sophisticated guidance for the industry, ensuring uniformity, differentiation, and standardization in compliance and testing.
Diagnostic & Therapeutic Imaging/Treatment Platform
An integrated theranostic technology platform combining diagnostics and therapeutics for image-guided therapy, advancing drug candidates through Phase Zero.
BI2TM
A blockchain technology and artificial intelligence platform designed to bridge the gap between cultivators, processors, R&D, Global Pharma/biotechnology and the medical community by providing an immutable ledger for supply chain data.
Services
Design and delivery of data procurement, management, analytics and visualization services linking agricultural and clinical datasets.
Design collaboration and implementation of automated and robotic laboratory workflows to increase testing throughput and standardization.
Programmatic testing, track-and-trace and certification services for agribiopharmaceutical products to support compliance and public-health oversight.
Coordination of master drug program agreements and relationships with contract manufacturers to expedite cGMP production of candidate therapeutics.
R&D services to develop integrated diagnostic–therapeutic approaches and to support early-phase clinical development and licensing strategies.
Structuring and managing sponsored research, MOUs and facility agreements with universities and international partners to advance diagnostic and testing capabilities.
Design and delivery of data procurement, management, analytics and visualization services linking agricultural and clinical datasets.
Design collaboration and implementation of automated and robotic laboratory workflows to increase testing throughput and standardization.
Programmatic testing, track-and-trace and certification services for agribiopharmaceutical products to support compliance and public-health oversight.
Coordination of master drug program agreements and relationships with contract manufacturers to expedite cGMP production of candidate therapeutics.
R&D services to develop integrated diagnostic–therapeutic approaches and to support early-phase clinical development and licensing strategies.
Structuring and managing sponsored research, MOUs and facility agreements with universities and international partners to advance diagnostic and testing capabilities.
Expertise Areas
- Integrated agribiopharmaceutical informatics
- AI-driven analytics for health and agriculture
- Laboratory automation and high-throughput testing
- Testing, certification and traceability for agribiopharmaceuticals
Key Technologies
- AI-driven analytics
- Integrated data management platforms
- Bioinformatics and medical informatics
- Image-guided theranostic technologies
News & Updates
Announcement of an agreement to develop an automated laboratory testing platform using robotics to advance testing capacity for public health and safety.
Partnership to support creation of a testing and certification laboratory for scientific analysis within cannabinoid research.
Announcement of a United States patent allowance for methods covering comprehensive medical cannabis and hemp testing from agriculture to clinical application.
Announcement of a master drug program agreement with a contract manufacturer to expedite cGMP production for diagnostic evaluation of COVID-19 antiviral agents.
Announcement that a theranostic platform is being repurposed for diagnosis, monitoring and treatment of viral infections.
Memorandum of understanding to develop a diagnostic approach intended to assess neurological disorder outcomes following treatments.
Announcement of an agreement to develop an automated laboratory testing platform using robotics to advance testing capacity for public health and safety.
Partnership to support creation of a testing and certification laboratory for scientific analysis within cannabinoid research.
Announcement of a United States patent allowance for methods covering comprehensive medical cannabis and hemp testing from agriculture to clinical application.
Announcement of a master drug program agreement with a contract manufacturer to expedite cGMP production for diagnostic evaluation of COVID-19 antiviral agents.
Announcement that a theranostic platform is being repurposed for diagnosis, monitoring and treatment of viral infections.
Memorandum of understanding to develop a diagnostic approach intended to assess neurological disorder outcomes following treatments.